Bayes Theorem Cystectomy Humans Laparoscopy Robotic Surgical Procedures Urinary Bladder Neoplasms/*surgery

Carcinoma Transitional Cell/secondary/*surgery Cystectomy/*adverse effects/methods Humans *Lymphatic Metastasis Neoplasm Recurrence Local/*epidemiology Peritoneal Neoplasms/epidemiology/*secondary Robotic Surgical Procedures/*adverse effects/methods Urinary Bladder Neoplasms/pathology/*surgery Atypical recurrence Bladder cancer Cystectomy Port-site metastases Rarc

Guidelines as Topic Humans Immunotherapy/*methods Societies Medical/*standards Urinary Bladder Neoplasms/*drug therapy antineoplastic protocols immunotherapy urinary bladder neoplasms urologic neoplasms Pfizer AstraZeneca Nektar Seattle Genetics DragonFly Therapeutics Non-CME services: Genentech AstraZeneca Merck Seattle Genetics Contracted research: Genentech Merck AstraZeneca Nektar Seattle Genetics Immunomedics. PCB─Consulting fees: AbbVie Asieris Pharmaceuticals Astellas AstraZeneca Bayer Biosyent Bristol-Myers Squibb EMD Serono Ferring Fergene H3 Biomedicine Janssen Merck Roche Sanofi TerSera Urogen Contracted research: iProgen. MTC─Consulting fees: Pfizer EMD Serono AstraZeneca Exelixis Eisai Seattle Genetics Astellas Contracted research: Exelixis Pfizer/EMD Serono Janssen Apricity Health. GSD─Participant/unpaid volunteer: HealthVibe focus group 2020. MDG─Consulting fees: Inovio NuMab Janssen Merck GlaxoSmithKline Genentech Bristol-Myers Squibb Seattle Genetics Dracen Dragonfly Astellas Novartis Pfizer AstraZeneca Incyte Dendreon Eli Lilly EMD Serono Aileron Therapeutics Ownership interest: Rappta Therapeutics NPI: 1639140668. PG─Consulting fees: AstraZeneca Dyania Health EMD Serono Immunomedics Janssen Merck Mirati Therapeutics Genentech Pfizer Seattle Genetics Contracted Research: Bavarian Nordic Bristol-Myers Squibb Clovis Oncology Debiopharm Immunomedics Pfizer Merck QED Therapeutics GlaxoSmithKline Kure It Cancer Research Mirati Therapeutics. SG─Consulting fees: Merck Bristol-Myers Squibb Janssen Seattle Genetics AstraZeneca Contracted research: Bristol-Myers Squibb Pfizer Non-CME services: Exelixis. CJH─Consulting fees: Astellas Bristol-Myers Squibb Genentech Merck Eisai Seattle Genetics 2bPrecise Non-CME services: Astellas Bristol-Myers Squibb Genentech Eisai Seattle Genetics. AMK─Consulting fees: Abbott Molecular Arquer ArTara Asieris AstraZeneca BioClin Therapeutics Bristol-Myers Squibb Cepheid Cold Genesys Eisai Engene Inc. Ferring FerGene Imagin Janssen MDxHealth Medac Merck Pfizer Photocure ProTara Roviant Seattle Genetics Sessen Bio Theralase TMC Innovation US Biotest Contracted research: Adolor Bristol-Myers Squibb FKD Industries Heat Biologics Merck Photocure SWOG/NIH SPORE AIBCCR Clinical trials: FKD Merck Bristol-Myers Squibb Photocure SWOG Adolor Heat Biologics Laboratory research: NIH SPORE AIBCCR Educational grant: CEC Oncology Editorial board: European Urology Oncology Journal of Urology UroToday President of organization: International Bladder Cancer Network (IBCN) International Bladder Cancer Group (IBCG) IP Rights: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) Joint with UT MD Anderson Cancer Center. LPL─Consulting fees: Pfizer Advisory Nursing board 2018 Lecture/Speaker/Expert Panel: ASCO Bladder Program 2019 Pfizer learning day 2019 ASCO Bladder Program Panel Member and Faculty 2019 Pfizer Learning Day Speaker 2019 BCAN Webinar Faculty 11/2020. JJM─Consulting fees: AstraZeneca Ferring Janssen Nucleix Foundation Medicine Contracted research: Epizyme Tesaro Abbvie Teaching an endoscopy course: Olympus. ERP─Consulting fees: AstraZeneca Infinity Pharma Pfizer Flatiron Genentech Merck Seattle Genetics Contracted research: Astellas Bristol-Myers Squibb Genentech Merck. JER─Consulting fees: Merck Bristol-Myers Squibb AstraZeneca Astellas Seattle Genetics Boehringer Ingelheim Bayer Pfizer Roche/Genentech Mirati QED Therapeutics Janssen Pharmacyclics GlaxoSmithKline Contracted research/Clinical trial funding: Seattle Genetics Astellas Roche/Genentech Bayer AstraZeneca QED Therapeutics. NS─Consulting fees: Amgen Astellas AstraZeneca Bayer Bristol-Myers Squibb Dendreon Fergene Ferring Janssen Merck Myovant Nymox Pfizer Sanofi/Genzyme Sesen Bio Sun Pharma Tolmar. GDS─Consulting fees: Merck Janssen Ferring Bristol-Myers Squibb Pfizer Genentech Epivax Oncology AstraZeneca Fidia Cold Genesys EnGene Bio Aduro Biotech Dendreon FKD Therapies CiClomed Seattle Genetics Urogen PhotoCure. SITC staff: SMW—Shares owned: Pacific Biosciences Editas Medicine EG AK BL LL─Nothing to disclose.

窄带成像 非肌层浸润性膀胱癌 经尿道膀胱肿瘤电切术 安全性 共识

*Carcinoma Transitional Cell Evidence-Based Medicine Humans *Radiology Societies Medical United States *Urinary Bladder Neoplasms/diagnostic imaging Auc Appropriate Use Criteria Appropriateness Criteria Bladder cancer Muscle invasive bladder cancer Nonmuscle invasive bladder cancer Surveillance Transitional cell carcinoma Urothelial cancer

Carcinoma Transitional Cell/*mortality/pathology/surgery Cystectomy Disease-Free Survival Humans Neoplasm Recurrence Local/*diagnosis/epidemiology/pathology Prognosis Risk Assessment/methods Urinary Bladder/*pathology/surgery Urinary Bladder Neoplasms/*mortality/pathology/surgery Urothelium/*pathology/surgery histology meta-analysis urinary bladder neoplasms

Radical cystectomy Vi-rads muscle-invasive bladder cancer urothelial carcinoma

Cystectomy/adverse effects/*methods Humans Laser Therapy/adverse effects/*methods Neoplasm Invasiveness Treatment Outcome Urethra Urinary Bladder Neoplasms/pathology/*surgery Bladder cancer Laser surgery Systematic review and meta-analysis Transurethral resection

Vi-rads bladder cancer bladder cancer staging inter-reader agreement multiparametric magnetic resonance imaging muscle-invasive bladder cancer

加速康复外科 快速康复外科 膀胱癌 腹腔镜 meta分析

Chemotherapy Adjuvant *Cystectomy/methods Humans Neoadjuvant Therapy Smoking/*adverse effects Survival Rate Treatment Outcome Urinary Bladder Neoplasms/drug therapy/*mortality/*surgery cigarette smoking cystectomy recurrence survival urinary bladder neoplasms

5 alpha reductase inhibitors androgen deprivation therapy androgen receptor bladder cancer

Carcinoma Transitional Cell/*surgery *Cystectomy Humans Male Neoplasm Recurrence Local Ureter/*pathology Urethra/*pathology Urethral Neoplasms/*surgery Urinary Bladder Neoplasms/*surgery

Humans Muscle Skeletal/*pathology Neoplasm Invasiveness ROC Curve Radiography/*methods Research Design Urinary Bladder Neoplasms/*diagnosis Bladder cancer Diagnostic imaging Magnetic resonance imaging

Biomarkers Carcinogens/analysis *Electronic Nicotine Delivery Systems Humans *Urinary Bladder Neoplasms/diagnosis/epidemiology/etiology *Vaping Bladder cancer Carcinogens Electronic cigarette Urinary biomarkers

Biomarkers Tumor/*metabolism Humans RNA Long Noncoding/*metabolism Urinary Bladder Neoplasms/*diagnosis/*genetics/pathology bladder cancer lncRNAs meta-analysis non-invasive diagnosis

Biomarkers/urine DNA Mutational Analysis DNA Neoplasm/*urine Disease Progression Humans Mutation Neoplasm Recurrence Local/*diagnosis/genetics/*urine Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnosis/genetics/*urine #BladderCancer #blcsm biomarkers molecular diagnostics urinary bladder neoplasms urine analysis Amsterdam UMC location VUmc. J. Bosschieter R.D.M. Steenbergen and J.A. Nieuwenhuijzen are inventors on patent(s) related to the work.

Anesthetics Local/*therapeutic use *Cystoscopy Humans Lidocaine/*therapeutic use Male Pain Management/*methods Pain Measurement Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/diagnosis/therapy administration cystoscopy intravesical lidocaine pain procedural urinary bladder neoplasms

Carcinoma Transitional Cell/diagnosis/epidemiology/*therapy Child Combined Modality Therapy *Disease Management Disease Progression Global Health Humans Incidence Risk Factors Survival Rate/trends Urinary Bladder/*pathology Urinary Bladder Neoplasms/diagnosis/epidemiology/*therapy Management Pediatric Surveillance Transurethral resection Urothelial cell carcinoma

Humans Patient Outcome Assessment *Patient Reported Outcome Measures Quality of Life Randomized Controlled Trials as Topic Reproducibility of Results Urinary Bladder Neoplasms/*diagnosis/pathology/psychology/*therapy Early bladder cancer Non-muscle invasive bladder cancer Patient-reported outcome measures Systematic review